Biography

Steven Soroka published latest article in Canadian journal of kidney health and disease entitled Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease: A Canadian Expert Consensus. This article is available in PubMed with an unique identification number PMID: 28321325 and it is published in 2017. The coauthors of this article are Soroka S, Alam A, Bevilacqua M, Girard LP, Komenda P, Loertscher R, McFarlane P, Pandeya S, Tam P, Bichet DG.


Research Interest

Healthcare


Latest Publication Details

Article Title: Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease: A Canadian Expert Consensus.

Co-Author(s): Soroka S, Alam A, Bevilacqua M, Girard LP, Komenda P, Loertscher R, McFarlane P, Pandeya S, Tam P, Bichet DG

Affiliation(s): Division of Nephrology, Dalhousie University, Halifax, Nova Scotia, Canada.

PMID 28321325, Year 2017

Abstract: Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited renal disorder worldwide. The disease is characterized by renal cysts and progressive renal failure due to progressive enlargement of cysts and renal fibrosis. An estimated 45% to 70% of patients with ADPKD progress to end-stage renal disease by age 65 years. Although both targeted and nontargeted therapies have been tested in patients with ADPKD, tolvaptan is currently the only pharmacological therapy approved in Canada for the treatment of ADPKD. The purpose of this consensus recommendation is to develop an evidence-informed recommendation for the optimal management of adult patients with ADPKD. This document focuses on the role of genetic testing, the role of renal imaging, predicting the risk of disease progression, and pharmacological treatment options for ADPKD. These areas of focus were derived from 2 national surveys that were disseminated to nephrologists and patients with ADPKD with the aim of identifying unmet needs in the management of ADPKD in Canada. Specific recommendations are provided for the treatment of ADPKD with tolvaptan.La polykystose r?nale autosomique dominante (PKRAD) est le trouble r?nal h?r?ditaire le plus fr?quent dans le monde. La maladie est caract?ris?e par la pr?sence de kystes r?naux et par une insuffisance r?nale progressive provoqu?e par l??largissement progressif des kystes et par une fibrose r?nale. Environ 45 ? 70% des patients atteints de PKRAD verront leur ?tat ?voluer vers l?insuffisance r?nale terminale avant l??ge de 65 ans. Bien que les th?rapies cibl?es et non cibl?es aient ?t? test?es chez des patients atteints de PKRAD, le tolvaptan est le seul m?dicament approuv? au Canada pour le traitement de la PKRAD. L?objectif de cette recommandation consensuelle est l??laboration de recommandations fond?es sur des donn?es probantes pour une prise en charge optimale des patients adultes atteints de PKRAD. Ce document met l?accent sur le r?le du d?pistage g?n?tique et de l?imagerie r?nale, sur les fa?ons de pr?dire le risque de progression de la maladie et sur les options de traitement pharmacologique de la PKRAD. Ces domaines d?action d?rivent de deux enqu?tes nationales diffus?es aux n?phrologues et aux patients canadiens atteints de PKRAD, et qui avaient pour but d?identifier les besoins non satisfaits dans la prise en charge le la PKRAD au Canada. Des recommandations sp?cifiques sont fournies pour le traitement de la PKD avec le tolvaptan.

Journal: Canadian journal of kidney health and disease

Related Citations

http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&cmd=link&linkname=pubmed_pubmed&uid=28321325

Related Citations XML

http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&cmd=link&linkname=pubmed_pubmed&uid=28321325&report=xml

RelatedArticles Review

http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&cmd=link&linkname=pubmed_pubmed_reviews&uid=28321325